Table 1

Inclusion criteria

Registration criteria	Randomization criteria
Age >18 Histology: High-grade serous cancer Endometrioid cancer Progressing ≥6 months after day 1 of the last cycle of first-line platinum-based chemotherapy and requiring treatment with platinum-based chemotherapy Relapsed disease CT/MRI proven Have had secondary debulking surgery Available FFPE tumor sample ECOG performance status 0–1 Informed consent	Completed 4–6 cycles of second-line platinum-based chemotherapy Response criteria: Measurable disease: CR/PR RECIST v.1.1 Non-measurable disease: GCIG CA125 response After secondary debulking surgery: no evidence of disease progression on CT/MRI CA-125 criteria First screening CA125 value is below the ULN If the first screening CA125 value is greater than ULN,^* second assessment required at least 7 days after the first to confirm eligibility. If the second CA125 has risen by 15%, patient not eligible.

Registration criteria

Randomization criteria

Age >18
Histology:
- High-grade serous cancer
- Endometrioid cancer
Progressing ≥6 months after day 1 of the last cycle of first-line platinum-based chemotherapy and requiring treatment with platinum-based chemotherapy
Relapsed disease
- CT/MRI proven
- Have had secondary debulking surgery
Available FFPE tumor sample
ECOG performance status 0–1
Informed consent

Completed 4–6 cycles of second-line platinum-based chemotherapy
Response criteria:
- Measurable disease: CR/PR RECIST v.1.1
- Non-measurable disease: GCIG CA125 response
- After secondary debulking surgery: no evidence of disease progression on CT/MRI
CA-125 criteria
- First screening CA125 value is below the ULN
- If the first screening CA125 value is greater than ULN,^* second assessment required at least 7 days after the first to confirm eligibility.
- If the second CA125 has risen by 15%, patient not eligible.